NEW DELHI: Leading PE firms and banks such as ICICI Venture, Yes Bank, GM Financial and Standard Chartered are learnt to be in talks with Ranbaxy's diagnostic chain, SRL Ranbaxy, for a minority stake ahead of the company's proposed IPO.
SRL Ranbaxy has received expressions of interest (EoI) from several financial funds and talks are at a fairly advanced stage. However, the company has not finalised the financial details or the stake it would offload before its public issue.
Continue Reading: http://economictimes.indiatimes.com/News/News_By_Industry/PEs_banks_in_talks_to_buy_stake_in_SRL_Ranbaxy/articleshow/2976754.cms
Saturday, April 26, 2008
ICRA assigns `LA` rating to Rs 0.50 bn NCD programme of SRL Ranbaxy
Rating agency ICRA assigned `LA` rating to Rs 0.50 billion non convertible debenture (NCD) programme of SRL Ranbaxy (Q, N,C,F)* (SRL). Rating indicates adequate credit quality in the long term.
The rating factors in SRL`s strong parentage, its pan-India presence in diagnostic industry and high quality standards maintained in test results. Over the years, SRL has focused on reducing delivery time for test results and expanding its geographical coverage and reach, which has led to substantial improvement in its turnover and profitability and enabled it to wipe out its accumulated losses.
Clinical trial laboratories in India
Clinical trials of bio-tech and medicinal products for approval purposes are done usually in hospitals in India. Most of the hospitals conduct clinical trials, if they have doctors interested in this activity. Information on the terms and conditions and the cost is not readily available.
All types of hospitals carry out clinical trials, large and small as also municipal and government hospitals. Large private hospitals and clinics too perform this work. The basic requirement is the presence of doctors who have an interest in this work.
On the basis of preliminary enquiries, there are already companies or agencies engaged exclusively for clinical trials in India. Examples are Quintiles in Ahmedabad, Clinfarm Consultants and Specialty Ranbaxy in Mumbai and Kumar in New Delhi. Quintiles and Specialty Ranbaxy have foreign tie-ups giving them the technological advantage over the purely local ones.
Continue Reading: http://indiaonestop.com/clinicaltrials.htm
Filling the vacuum in quality healthcare, diagnostic services
| Filling the vacuum in quality healthcare, diagnostic services | |
| Ameera Patel / Mumbai Apr 19, 2008 09:39 | |
| Filling the vacuum in quality healthcare, diagnostic services metropolis identifies opportunities and trends in the coming financial year | |
| Introduction Healthcare, globally, is on a high-growth trajectory, with strong emphasis on the Asian and Middle East markets. Currently the global healthcare market is valued at over USD 6.68 trillion, 2005, and is growing at rate of 7.5%, which is much higher than the global GDP growth. It is estimated that Asia currently constitutes around 34% of the healthcare market. This figure is expected to increase to about 45% by 2008 and projects opportunities for the Indian health care in the global pharmaceutical and diagnostic markets. The Indian healthcare industry alone is ready to rocket from a USD 20.6 billion industry in 2001 to an expected USD 60 billion by 2010, led by strong demand. The Indian healthcare industry employs over four million people, which makes it one of the largest service sectors in the economy. The extended reach of healthcare due to the advancement in technology and creation of an E-world has led to Remote diagnostics, surgeries, monitoring of chronic conditions; Specialist conditions; Email consultations for primary care; E-prescriptions; Electronic health records and Telemedicine, which has further led to borderless healthcare services. Continue Reaading: http://www.indiainfoline.com/news/innernews.asp?storyId=65195&lmn=1 |
Nicholas Piramal's Wellspring Acquires 100 pc Stake In Dr Phadke's Path Labs
Wellspring, the chain of pathology laboratories and diagnostic centres promoted by Nicholas Piramal India Pvt Ltd (NPIL), has acquired the remaining 40 per cent stake in its joint venture with Dr Phadke's Path Labs in Mumbai. The entity, thereafter will be renamed as Wellspring-Dr Avinash Phadke Pathlab and Diagnostics. This will make Wellspring India's largest pathology laboratory chain.
Continue Reading: http://www.expresshealthcaremgmt.com/200610/innews02.shtml
Monday, April 21, 2008
Sneha Diagnostics plans 10 medical diagnostic centres
Introduction
Sneha Diagnostics has unveiled plans to open 10 diagnostic centres in all major district centres across the state of Andhra Pradesh, India. After completing the first phase, it desires to go for a public issue and / or venture capital with a focus to reach remote corners of India. Sneha Diagnostics currently owns and operates three diagnostics centres in the towns of Ongole and Chirala of Prakasam District and Kavali of Nellore District in Andhra Pradesh, India.
Location
The new facilities will be located in all major district centres of Andhra Pradesh, India. The organisation has plans to set up more centres in second-tier cities and remote places all over India.
Sneha Diagnostics has unveiled plans to open 10 diagnostic centres in all major district centres across the state of Andhra Pradesh, India. After completing the first phase, it desires to go for a public issue and / or venture capital with a focus to reach remote corners of India. Sneha Diagnostics currently owns and operates three diagnostics centres in the towns of Ongole and Chirala of Prakasam District and Kavali of Nellore District in Andhra Pradesh, India.
Location
The new facilities will be located in all major district centres of Andhra Pradesh, India. The organisation has plans to set up more centres in second-tier cities and remote places all over India.
Continue Reading : http://www.asianhhm.com/knowledge_bank/projects/sneha_diagnostics.htm
Saturday, April 19, 2008
Medical Industry Diagnosis: Triage for Health Care and New Vision for Life Sciences
If inefficiency is the path to opportunity, the future for India's health care sector may be bright. Just how close that future is varies by market segment. In the case of life sciences, its arrival could coincide with industry participants' greater willingness to accept risk, while health insurance could seize its day amid rising treatment costs. As for health care delivery's chance to shine, that could be more in the distant future, stymied by a lack of infrastructure investment and trained professionals.
Two recent conference panels, one at Wharton and the other at Harvard University, explored the state of India's health care system. Among the conclusions: Government and industry need to increase health care investment and employment and make high-quality care more affordable and available to all.
The Wharton India Economic Forum panel titled, "India's New Mandate: Addressing the Health Care Paradox," portrayed a system of contradictions. On the one hand, medical tourism is on the rise. On the other, tuberculosis seems unstoppable in certain states. "Paradox is one characterization," said Bhaven Sampat, professor of health care management at Columbia University and panel moderator. "But challenge is another. Like every rapidly developing country, India is faced with the challenge of how to manage growth with distribution, how to balance equity with efficiency, and how to ensure that as parts of the Indian health care sector enter the worldwide elite, the masses are not left behind."
Continue Reading: http://knowledge.wharton.upenn.edu/india/article.cfm?articleid=4277
Fortis Group cos SRL Ranbaxy & Fortis Healthworld planning stake sale to PEs
NEW DELHI: Fortis Group companies—diagnostic chain SRL Ranbaxy and retail chain Fortis Healthworld—are considering a strategic alliance to offload minority stakes to private equity (PE) players to part fund their respective expansion plans.
A source told ET, "SRL Ranbaxy is in advanced talks with a few PE firms as part of the pre-IPO sale. The company is looking at forging a strategic alliance with Fortis Healthworld, wherein the latter would also divest some of its stake.
There is a possibility that a PE fund may get to pick up stakes in both the companies. Officials of both Fortis Healthworld and SRL Ranbaxy—separate companies of the Fortis Group — were not available for comment.
A source told ET, "SRL Ranbaxy is in advanced talks with a few PE firms as part of the pre-IPO sale. The company is looking at forging a strategic alliance with Fortis Healthworld, wherein the latter would also divest some of its stake.
There is a possibility that a PE fund may get to pick up stakes in both the companies. Officials of both Fortis Healthworld and SRL Ranbaxy—separate companies of the Fortis Group — were not available for comment.
'We are leading from the front'
The 4th International Conference on Clinical Research recently took place in Mumbai and undertook a volley of vital topics. Arshiya Khan and Aashruti Kak report
"Clinical trials market will drive the growth of the clinical diagnostics market," predicted Dr Rajat Goyal, Vice President-Clinical Operations, Asia Pacific, ICON Clinical Research, at the International Conference on 'Global Trends in clinical research' on 14 and 15 March, 2008, in Mumbai. The global demand for clinical research to be undertaken in India has expanded significantly over the last five years. A considerable interest has been focused upon 'outsourcing' of clinical research to India. The domestic pharmaceutical industry has also rapidly begun evolving into a global player. This conference highlighted the fundamental opportunities and challenges faced by all, conducting clinical research in India through solution driven sessions presented by experts, from industry and academia, with practical global experience.
continue reading: http://www.expresspharmaonline.com/20080415/market08.shtml
Arkray Piramal Launches Highly Advanced Glucose Self-Monitoring Device
April 8, 2008 ( PowerHomeBiz ) - Mumbai, India --- Arkray Inc., a Japan-based innovator company, makers of the world's first-ever diabetes self-monitoring device and specialists in diabetes care and diagnostics, in partnership with Piramal Healthcare, has recently launched Glucocard 01, a highly advanced glucometer.
Glucocard 01 offers a high level of accuracy and precision in the self-monitoring of blood glucose due to the use of sophisticated and unique biosensor technology. In addition, Glucocard 01 ensures a virtually pain-free testing experience for the diabetic patient.
Biosensor technology is accepted as being superior, since its accuracy and precision are far greater than obtained with photometer technology, which is commonly used in other glucometers.
Continue Reading: http://www.powerhomebiz.com/News/042008/arkray-piramal.htm
Opto Circuits completes acquisition of Criticare Systems
Opto Circuits (India) Limited, India's leading manufacturer of medical diagnostics and interventional products, today announced that it has successfully completed acquisition of Criticare Systems, Inc, a leading USbased healthcare ...
Read complete story:
Sunday, April 13, 2008
Diagnostics biz set to boom
With the recent notification of the revised schedule Y of the Drugs & Cosmetics Act allowing simultaneous Phase II & III trials in India and the rest of the world, clinical research outsourcing to India is set to boom. With current revenues of $100 million, the clinical research industry is set to grow 80% in 2005, predicts market-research firm SCOPE. While CenterWatch estimates the industry to reach a size of $300 million in the next five years, others like The Boston Consulting Group are more bullish projecting a $500 million turnover by 2010. It is estimated that 20% of all global clinical trials will be from India by then.
Read complete story: http://www.financialexpress.com/old/fe_full_story.php?content_id=88619
Saturday, April 12, 2008
Seedfund and Aavishkaar in Joint Investment for Vaatsalya
Seedfund, India's leading early-stage venture capital firm, and Aavishkaar India MVCF, have entered into a joint equity investment for Vaatsalya, a healthcare services startup which already has its hospitals in North Karntaka. The healthcare company is spearheading the establishment of India's first hospital network in semi-urban areas within the country and will offer primary and secondary care services
"This investment will enable Vaatsalya to create additional hospitals to provide much needed efficient and affordable healthcare services for large semi urban and rural families across India," said Dr. Ashwin Naik, Founder/CEO, Vaatsalya Healthcare Solutions Pvt. Ltd.
Although India's metros and semi-urban areas are witnessing the mushrooming of corporate healthcare chains, basic healthcare services available in semi-urban and rural India have a long way to go. A commitment to bridge this gap in healthcare equity in semi-urban and rural areas formed the basis for birth of the very first Vaatsalya Hospital in the year 2005.
Read complete story: http://www.indiaprwire.com/pressrelease/health-care/200804118712.htm?aid=2583Thursday, April 10, 2008
How rare is your rarest blood group? If you are a special blood type found in only one in 100, please enlist in Voluntary Blood Donors Hotline
Blood is a lifeline. Timely blood donation saves many. Everybody has it and everybody needs it. But, nobody donates it. Donate blood. Save lives. Especially rare blood group donors must come forward and donate blood
Read Complete story: How rare is your rarest blood group? If you are a special blood type found in only one in 100, please enlist in Voluntary Blood Donors Hotline
Wednesday, April 9, 2008
Profile: Lucid Diagnostics, Hyderabad, India
Medical Diagnostics is a comprehensive health care facility with dedicated resources for enhancement of health. Designed to be one of the most advanced imaging centers in India, it has brought the finest Medical Technology to south India. Combined with a comprehensive team of Health Care Professionals, LUCID is here to deliver superior service for individuals from all walks of life.
At LUCID we believe that there's more to patient care than simply providing care to patients. For one, it means providing our patients with the highest level of dignity and respect. It also means that our patients and referring doctors should receive the most comprehensive medical imaging technology and the highest level of professional expertise in the industry. After all, what good is having the equipment without the appropriate care?
Our goal is to provide the finest in imaging services – the right procedure, at the right time, for each individual patient.
At LUCID we believe that there's more to patient care than simply providing care to patients. For one, it means providing our patients with the highest level of dignity and respect. It also means that our patients and referring doctors should receive the most comprehensive medical imaging technology and the highest level of professional expertise in the industry. After all, what good is having the equipment without the appropriate care?
Our goal is to provide the finest in imaging services – the right procedure, at the right time, for each individual patient.
| |
Our Mission
Plot No. 18, Rao & Raju Colony, Road No. 2, Banjara Hills, Hyderabad. Tel: +91 40 23553355, 23550077, 23550088, Fax: +91 40 23609222 e mail: kpraju@luciddiagnostics.com | |
For more information visit their web-site: http://www.luciddiagnostics.com/
Tuesday, April 8, 2008
India needs 600,000 more doctors: Plan Panel
Painting a grim picture on the healthcare sector, the Planning Commission has blamed the shortage of medical professionals for the dismal scenario. There was a requirement of at least 600,000 more doctors, it said.
The situation is particularly bad in the public healthcare sector, a high-level group of the Commission said in a report last week.
The public healthcare has been on a serious decline during the last two or three decades because of non- availability of medical and paramedical staff, diagnostic services and medicines.
Read Complete story: http://www.rediff.com/money/2008/apr/07panel.htm
Monday, April 7, 2008
We're aiming to build an umbrella brand: Iven Medicare, a new company, will invest in a network of hospitals that will be run by owner entrepreneurs
As India's oldest and largest private equity (PE) player, ICICI Venture Fund Management Co. Ltd sets the trend for peers in the emerging business space. This time around, the PE firm is raising $250 million (around Rs1,000 crore) to be invested in the country's burgeoning health care segment.
The funds will be used to roll out multiple networks of hospitals across urban and semi-urban centres, and will also be used to build the firm's growing interest in allied segments such as pathology laboratories and specialized health care services.
Read compelete story: http://www.livemint.com/2008/04/06234933/8216We8217re-aiming-to-b.html
The funds will be used to roll out multiple networks of hospitals across urban and semi-urban centres, and will also be used to build the firm's growing interest in allied segments such as pathology laboratories and specialized health care services.
Read compelete story: http://www.livemint.com/2008/04/06234933/8216We8217re-aiming-to-b.html
Now, monitor your health at your personal computer with new saliva diagnostic tool
April 6 : Scientists at the University of California, Los Angeles have made diagnostic tools more accurate, convenient and non-invasive, by developing Salivaomics Knowledge Base (SKB), a saliva diagnostic atlas that can work on computer or via computer simulation.
Launched during the 37th Annual Meeting of the American Association for Dental Research in Dallas, Texas, the SKB promises to serve as a catalyst for future development and expansion of salivary diagnostics.
Read complete story: http://www.ebiologynews.com/4232.html
Friday, April 4, 2008
SRL Ranbaxy & Fortis Healthworld planning stake sale to PEs
Fortis Group companies—diagnostic chain SRL Ranbaxy and retail chain Fortis Healthworld—are considering a strategic alliance to offload minority stakes to private equity (PE) players to part fund their respective expansion plans.
SRL Ranbaxy is in advanced talks with a few PE firms as part of the pre-IPO sale. The company is looking at forging a strategic alliance with Fortis Healthworld, wherein the latter would also divest some of its stake.
According to industry sources, the diagnostic and retail chain companies share a lot of synergy being in the same sector. As such, SRL Ranbaxy can leverage its brand value and support its pharmacy retail partner, which is a relatively new model in India.
Interview with Dr. Hiran,Assistant Professor, Department of Pathology, Amrita Institute of Medical Sciences and Research Centre, Cochin.
Pathology is basically a sciences and clinical practice concerned particularly with structural and functional changes in tissues and organs of the body caused by disease. In fact,
the strength of the pathologists is to keep their much deserved prominence in modern medicine resides in their unique intellectual ability to sum up and integrate an enormous amount of anatomical, histological, cytological, and molecular data -obviously obtained by various methods-and to correlate this with clinical data for establishing an accurate diagnosis and prognosis.
the strength of the pathologists is to keep their much deserved prominence in modern medicine resides in their unique intellectual ability to sum up and integrate an enormous amount of anatomical, histological, cytological, and molecular data -obviously obtained by various methods-and to correlate this with clinical data for establishing an accurate diagnosis and prognosis.
Asian CROs poised for substantial growth
03-Apr-2008 - The Asia Pacific region is poised to witness heightened activity in terms of outsourced drug development to contract research organisations (CROs), with India and China remaining the preferred destinations.
Recent estimates by Frost & Sullivan have determined that Asian CROs conducting Phase I-IV research earned revenues of $1.2bn in 2006, with the figure expected to reach $2bn in the next two years.
Read complete story: http://www.outsourcing-pharma.com/news/ng.asp?n=84302-biotechnology-contract-research-organization-asia-pacific
Tuesday, April 1, 2008
Profile: Dr. Lal Path Labs, Delhi, India
Dr.Lal Path Labs was established in 1949 by Major S.K. Lal. One of India's largest medical diagnostics company, it is primarily Delhi-based, though it has a pan-India presence. The total employee strength stands at 900. The technical core works hand-in-hand with the commercial wing in an ongoing attempt to scale-up operations.
The Growth Story
The company expanded rapidly to other parts of north India and across the country, such as Kolkata, Bombay and Bangalore. Starting with about 10 labs in 2005, today that number stands at 27 and plans are afoot to take this number to 50 by March 2009. Delhi itself presently has 7 satellite labs.
The company expanded rapidly to other parts of north India and across the country, such as Kolkata, Bombay and Bangalore. Starting with about 10 labs in 2005, today that number stands at 27 and plans are afoot to take this number to 50 by March 2009. Delhi itself presently has 7 satellite labs.
"Our priority is ERP": says Lal path Labs
LPL was the first Indian company to make extensive use of IT. Our entire lab operation is IT driven. We are currently using Centercity ULTRA, a software solution from GE Health Care, as laboratory information system (LIS) which is the industry standard. We have deployed ULTRA for the entire lab operations, as all the labs are connected with the central location through leased lines.
Read complete story: http://www.ehealthonline.org/interview/interview-details.asp?interviewid=383
Subscribe to:
Posts (Atom)
